Abstract 2338P
Background
Ovarian cancer (OC) is one of the most common gynecological cancers, with the worst prognosis and the highest mortality rate. According to the FIGO, the overall five-year survival rate is approximately 50%. Tumor-associated macrophages (TAMs) are one of the most prominent populations of immune cells in both ovarian cancer tissue and malignant ascites. The most relevant task is to identify TAM subpopulations in ovarian cancer, to discover how they interact with chemotherapy and affect the development and outcome of the disease.
Methods
Patients with high-grade serous ovarian carcinoma were included in the study. FFPE samples with tumor were obtained after surgery. The study was carried out according to medical ethics. We applied two technologies of spatial transcriptomics for the analysis of TAM transcriptomic features in patients with ovarian cancer – 10x Genomics Visium and Nanostring GeoMX-DSP. All procedures were performed according to manufacturer`s protocols.
Results
The results of 10x Visium demonstrated that TAM cluster express CCL18, APOC1, GPNMB, LYZ, APOE, C1QC, C1QB, CTCB, SPP1, CTSS, and other genes. Interestingly, according to accumulating data the expression of these macrophage markers is distinctive feature for the potentially targeted population of lipid-associated TAMs. The morphology of macrophages in TAM cluster in clinical samples corresponds to the large lipid-associated TAMs. Nanostring technology allowed us to analyse ROIs with immune cells located in different tumor sites. The transcriptome of TAMs located near the tumor nest correlated to functional activation of extracellular matrix organization, antigen presentation, vascular development and myeloid leukocyte activation. These TAMs have the same morphology of large foamy macrophages and express APOE, SPP1, LYZ, CTSS, and other genes.
Conclusions
We found gene signature specific for the large TAMs in tumor tissue of patients with high-grade serous ovarian carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation research project No 21-75-10021.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2325P - Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
Presenter: Rafael Rosell
Session: Poster session 16
2326P - Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy
Presenter: Michele Ghidini
Session: Poster session 16
2327P - The impact of the microenvironment on the intratumoral cellular heterogeneity in colorectal cancer
Presenter: Idan Carmi
Session: Poster session 16
2328P - Alternative molecular mechanisms underpinning breast invasive lobular carcinoma identified by genomics-driven artificial intelligence model
Presenter: Fresia Pareja
Session: Poster session 16
2329P - Evidence for the utility of artificial intelligence and image analysis in Ki-67 quantification in solid tumors
Presenter: Xavier Pichon
Session: Poster session 16
2331P - Interest of next generation sequencing (NGS) for integrated molecular diagnosis of HER2-low breast cancer
Presenter: Jean Louis Merlin
Session: Poster session 16
2332P - Overall survival in breast cancer patients with HER2-low status single- center experience
Presenter: Joanna Huszno
Session: Poster session 16
2333P - Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancers
Presenter: Anna Karlsson
Session: Poster session 16
2334P - Pathologic patterns following different neoadjuvant therapies in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster session 16